ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 222

Lung Nodules in Patients with Idiopathic Inflammatory Myopathies

Laura C. Cappelli1, Andrew L. Mammen2, Sonye K. Danoff3, Grant H. Louie4, Thomas E. Lloyd5 and Lisa Christopher-Stine6, 1Ste 4500, Johns Hopkins University, Baltimore, MD, 2NIAMS, NIH, Bethesda, MD, 3Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, 4Rheumatology, Johns Hopkins University, Baltimore, MD, 5Neurology, Johns Hopkins, Baltimore, MD, 6Medicine and Neurology, Johns Hopkins University, Baltimore, MD

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Lung, myositis and polymyositis/dermatomyositis (PM/DM)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Clinical and Therapuetic Aspects of Idiopathic Inflammatory Myopathies

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The idiopathic inflammatory myopathies are associated with an increased incidence of malignancy, and interstitial lung disease (ILD) has been reported in as many as 20-78% of patients with polymyositis and dermatomyositis when followed from diagnosis.  As a result of these associations, patients often receive CT scans of the chest where lung nodules are incidentally discovered. The radiographic nature of these lung nodules and whether they tend to increase in size, regress, or remain stable in size has not been described. The aim of this study was to define the prevalence of lung nodules in patients with inflammatory myopathies in a large clinical cohort evaluated at a Myositis Center, the clinical features associated with the presence of lung nodules, and whether the nodules changed in size over time.

Methods:

Data was obtained from the cohort of 976 patients referred to the Myositis Center at Johns Hopkins.  Only patients with confirmed inflammatory myopathies and at least one chest CT scan performed at our Center for clinical purposes were included in the study.  For patients with more than one CT, all CTs were reviewed. The presence of interstitial lung disease was defined by decreased total lung capacity (TLC) or diffusion capacity (DLCO) on pulmonary function testing and/or presence of ground glass opacities on chest CT.

Results:

298 of the 976 patients had at least one chest CT performed at our Center.  The prevalence of lung nodules in these patients was 25.5% (76/298). Only 5 patients had a nodule> 10 mm, and in those patients with follow up CTs, none of these nodules increased in size. Interstitial lung disease was present in 34.9% of the total cohort.  The prevalence of nodules was not significantly different in those who had interstitial lung disease and those who did not (26.9% and 24.7% respectively, p=0.68).  Of the 76 patients with lung nodules, 39.4 % (30/76) had a follow-up chest CT.  The interval for follow-up was variable and ranged from 3 to 19 months. On subsequent CTs, none of the nodules had progressed in size by more than .2 cm and 51.6% (16/31) had regressed entirely. 

Conclusion: Lung nodules are frequently observed in patients with inflammatory myopathies, but not greatly increased in prevalence over healthy adults where they are reported in 18% of patients.  Lung nodules were no more common in patients with ILD than those patients without ILD. The lung nodules do not likely represent malignancy as they do not progress when followed over time. In fact, about half of patients had regression of the nodules,


Disclosure:

L. C. Cappelli,
None;

A. L. Mammen,

anti-HMGCR antibody test,

;

S. K. Danoff,
None;

G. H. Louie,

UCB,

5;

T. E. Lloyd,
None;

L. Christopher-Stine,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lung-nodules-in-patients-with-idiopathic-inflammatory-myopathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology